BroadenBio Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BroadenBio Co., Ltd. - overview
Established
2018
Location
Beijing, -, China
Primary Industry
Biotechnology
About
Based in Beijing, China and established in 2018, BroadenBio Co. , Ltd. operates as a biopharmaceutical company that focuses on immuno-oncology and autoimmune diseases fields. Mr.
Xingmin Zhang is the founder and CEO of the company. In December 2025, the company raised CNY 100 million in series A+ funding from E-Town International Industrial Investment, BCT Capital and Lapam Capital. The company works with clinical research institutions and healthcare stakeholders to develop novel small-molecule therapeutics. Its pipeline includes BB102, a FGFR4 inhibitor in Phase II clinical trials for hepatocellular carcinoma, BB3008 in Phase Ib clinical development with immunomodulatory properties, and multiple preclinical candidates addressing oncology and autoimmune disease indications.
The company plans to advance its lead clinical programs, expand its preclinical pipeline and progress selected assets toward international clinical development and regulatory pathways.
Current Investors
Lapam Capital, Tao Capital, Beijing Ruihai Xiangda Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceuticals
Website
www.broadenbio.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.